A pilot study among patients with Alport syndrome was also done regarding the use of mineralocorticoid receptor antagonist in addition to RAS and SGLT2 inhibition, which showed an appreciable reduction in proteinuria when used concurrently [10]. The gene discussed is NR3C2; the disease is Alport syndrome.